According to clinical trial analysis, angiotensin-converting enzyme inhibitors are more effective in reducing myocardial hypertrophy than other antihypertensive drugs, indicating that the reversal of myocardial hypertrophy is more significantly affected by changes in angiotensin II than by blood pressure reduction [21]. The gene discussed is AGT; the disease is cardiac hypertrophy.